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Epilepsy is a common disorder affecting approximately 1% of the population. 
It is estimated that about 20- 30% of the patients become refractory to proper 
medical therapies. Such cases are often termed intractable. Intractable epilepsy 
(IE) is a serious condition in children, leading to significant impairment in quality 
of life, as well as behavioral and psychiatric problems. 
In this review, we tried to define intractability, mention the causes of intractable 
epilepsy and its predictive factors in children, and outline the management and 
various treatments of intractable epilepsy.
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Introduction
Epilepsy is a chronic neurologic condition characterized by recurrent, unprovoked 
seizures requiring continuous medication for long-term management (1). Epilepsy 
is a common disorder affecting approximately 1% of the population. It is estimated 
about 20-30% of patients become refractory to medical therapy (2), (3), (4), (5), 
(6). Such cases are often termed intractable. Intractability, however, is not evenly 
distributed among patients with epilepsy. It is more common in those with mental 
retardation, neurological deficits, or both, and generally in patients with detectable 
structural brain damage (7).
Intractability includes all patients who do not achieve complete control of (disabling) 
seizures (8). Medical intractable epilepsy is therefore usually defined as continued 
seizures in children despite adequate therapy with three or more Anti Epileptic 
Drugs (AEDs), used alone, serially, or in combinations (3), (9).
Intractable Epilepsy (IE) is a serious condition in children, leading to significant 
impairment in the Quality of Life (QOL), as well as behavioral and psychiatric 
problems including depression, sleep disorders, mood disorders, cognitive delay 
and poor scholastic performance. Most patients become severely emotionally 
affected, and coping with this chronic handicap may pose a burden on the family as 
well as on social, educational, and health services (10), (11). In addition, numerous 
medical problems, some of which are potentially life-threatening, arise as a result 
of uncontrolled seizures including aspiration, cardiac arrhythmias, electrolyte 
imbalances, brain edema, renal failure, unexplained sudden death, and refractory 
status epilepticus (12). Besides, these children are more prone to drug toxicity and 
drug interactions resulting from polypharmacy and are at higher risk of developing 
behavioral and academic difficulties (13).
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It is best to refer cases of intractable epilepsy early to a 
tertiary center for appropriate evaluation as well as to 
get guidance on management options like newer AEDs, 
the ketogenic diet and surgery.
Causes of intractable epilepsy
Intractability here is taken to mean epilepsy that is not 
controlled after an adequate trial of first line conventional 
anti epileptic drugs, singly or in combination. It is not 
the frequency of seizures as such that defines them as 
intractable, but rather their resistance to be controlled 
by treatment. When confronted with a child with 
apparently intractable epilepsy, three questions need to 
be considered:
(1) Does the patient have epilepsy? 
(2) What is the underlying cause/diagnosis?
(3) Is the epilepsy truly intractable?
1) Does the patient have epilepsy?
It is estimated that 20 to 30% of the patients referred 
for the management of intractable epilepsy do not have 
epilepsy (14), (15), (16), (17).
There are a large number of common non-epileptic 
paroxysmal disorders in childhood and it behooves the 
clinician who deals with epilepsy to be familiar with 
them.
Complementary information is given by the 
electroencephalogram (EEG). Paroxysmal activities 
on the EEG do not mean that a patient’s attacks are 
necessarily epileptic in nature. Video Monitoring of a 
seizure during EEG recording is extremely helpful. In 
cases with very frequent attacks, long term monitoring 
with a Video EEG and polygraphy may help resolve the 
issue.
2) What is the underlying cause/diagnosis?
In some cases the cause is obvious, such as asphyxial 
brain damage, a congenital infection, cerebral 
malformation, or a metabolic disorder. 
One important, recently uncovered factor in the 
development of intractable epilepsy is the overexpression 
of a variety of drug resistance proteins or their genes in 
the brain tissue.
This overexpression has been observed in the brain 
tissues taken from areas of cortical dysphasia, 
hippocumpal sclerosis, and tubers from patients with 
refractory epilepsy (18).
Several proteins have been implicated to date, and all 
belong to the ATP-binding cassette superfamily that 
also has been associated with resistance of cancer cells 
to antineoplastic agents.
They are Multi Drug Resistance gene-1-P-Glycoprotein 
(MDR1), Multidrug Resistance-associated Proteins 
(MRP1& MRP2) and the Major Vault Protein (MVP). 
By contrast, control tissues have no or low expression 
of these four types of proteins (19, 20).
Because these multidrug transporters restrict the entry of 
lipophilic molecules, such as many of the antiepileptic 
drugs, into brain, their overexpression reduces effective 
drug concentration at target sites. It is not clear, 
however, whether overexpression of these proteins is 
the cause or the result of intractable seizures. In animal 
Models, recurrent seizures have been shown to induce 
the multidrug resistance gene, and antiepileptic drugs 
have been able to up-regulate MDR1 and some other 
multidrug transporters. From these data, is suggested 
that there could also be a genetic contribution to drug 
resistant epilepsy (18).
However, in many cases, this is not so and there is 
always the question whether there is an underlying 
neurodegenerative disease.
All cases of intractable epilepsy should have a high 
resolution computed tomography, and even better, 
magnetic resonance imaging of  the brain, to detect 
brain structural defects. 
Although there are a large number of neurometabolic 
diseases in which seizures are prominent, most of them 
will be suggested by other clinical features. There are, 
however, a few conditions in which intractable epilepsy 
may be the most prominent initial feature. Pyridoxine 
dependency should always be excluded, particularly 
in infantile epilepsy; because prompt diagnosis and 
treatment can stop and prevent these seizures and 
consequential developmental disabilities.  (21), (22), 
(23).
It is important to classify the type of the seizures. The 
seizure type may provide a clue to the cause of the 
seizure disorder. Precise delineation of the seizure may 
allow a firm basis for making a prognosis and choosing 
the most appropriate treatment (24).
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3) Is the epilepsy truly intractable?
When reviewing the history of previous treatments 
it is necessary to document the following for each 
antiepileptic drug: the duration of treatment, dose/kg, 
clinical effects, side effects, and blood concentrations. 
If a drug has been stopped after a very short time the 
reason for changing it needs to be determined. When 
such a drug history is available it should be clear 
whether there has been an adequate trial of each drug, 
alone or in combination. Given the spontaneously 
fluctuating nature of most types of epilepsy, each 
trial of drugs or combination should be given for a 
minimum of one month (unless there is a severe side 
effect or exacerbation of seizures). For this reason it is 
normally preferable that drug changes occur at home 
and be monitored in outpatient setting rather than in a 
hospital. This will prevent the physician from changing 
the drug in a few days after starting, in a hospitalized 
child with uncontrolled seizures. It is also important to 
decide whether an adequate dose of each drug has been 
administered. In this regard the concept of a “therapeutic 
range” of blood concentrations for antiepileptic drugs 
is not particularly helpful. Persistently low blood 
concentrations may indicate non-compliance, which 
is an important cause of “poor seizure control”. A drug 
history such as this may reveal that an insufficient trial 
of one or more drugs may have been given and in some 
patients, going back to an antiepileptic drug that has 
previously been tried in a different dose or combination 
is sufficient to control the seizures. The possibility that 
the treatment is making the epilepsy worse must always 
be considered. It is probable that all the commonly 
used antiepileptic drugs aggravate seizures at some 
time, for example (Carbamazepine/Oxcarbazine may 
worsen and sometimes even induce absence/myoclonic 
seizures (25), (26), Gabapentin may increase complex 
partial seizures in some patients (27)) and some 
drugs (penicillin, INH, theophyline, insulin, lithium, 
prednisolone, oral contraceptive pills, chloroquine etc.) 
can be epileptogenic (27).
Occasionally, seizures will improve on decreasing or 
stopping drugs (28); more often, however, the seizures 
remain the same, but alertness and coordination improve 
(29).
Predictive factors in intractable epilepsy
Accepted various predictive factors in IE (27), (30) are 
listed in table 1:
Table 1: Predictive factors in intractable epilepsy.
 Seizure Type
1.Partial seizures
2. Multiple seizure types
3. High seizure frequency
4. Seizure onset in infancy
5.Febrile seizures.
6. Non idiopathic (non-inherited)
7. Specific Epilepsy Syndromes (e.g, West Syndrome, 
LennoxGaustat Syndrome)
8. Myoclonic seizures
9. Neonatal seizures  
 Clinical
1.Focal neurological deficit





7. CT scan abnormalities 
8. Sex (male)
Etiological
1. Organic brain lesions (e.g, mesial temporal lobe sclerosis, 
tuberous sclerosis, congenital cerebral anamolies etc.)
2. Head trauma
3. CNS infections
4. Hypoxic ischemic encephalopathies
5. Metabolic disturbances (phenylketonuria, maple syrup 
urine disease, mitochondrial encephalopathy).
Management
The general principles of managing intractable seizures 
are as follows (27):
• Review diagnosis and history of the epilepsy. The 
types of seizures and the epilepsy syndrome should 
be classified on the basis of clinical features and 
INTRACTABLE EPILEPSY IN CHILDREN
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the EEG. In addition, imaging of the brain with 
high quality MRI is appropriate, looking for an 
underlying structural lesion.
• Check serum concentrations of AEDs.
• Review past and present AED treatment.
• Select the AED that is most likely to be efficacious 
and with the fewest side effects.
• Adjust the dose of the selected drug to the optimum 
with increments made if seizures continue and side 
effects do not occur.
• Attempt to reduce and discontinue other AEDs, 
particularly those that have not aided seizure control 
and are suspected of giving rise to adverse effects.
• If seizures continue despite a maximal tolerated dose 
of a first line AED, another first line drug should 
then be commenced, and increased to an optimal 
dose.
• If combinations of two first line AEDs is unhelpful, 
the drug which appears to have the most effect and 
fewest side effects should be continued, and the 
other AED be replaced with a second-line drug. 
• If the second line drug is ineffective, withdrawal of 
the initial agent should be considered.
• Considered using a novel AED. Because of the 
limited clinical experience with newer AEDs it 
appears appropriate to recommend these drugs for 
the patients with refractory seizures in whom other 
drugs are not effective or cause intolerable side 
effects. 
• The above-mentioned scheme will generally take a 
number of months or even years to work through. If 
satisfactory control cannot be obtained with drugs, 
consider the possibility of surgical treatment of the 
epilepsy.
Other treatments:
Up to 70-80% of the patients with epilepsy can be 
seizure free with antiepileptic drugs (AEDs) (31), (32), 
and chronic epilepsy or medically refractory epilepsy is 
seen in about 20-30% of cases.
Options for the Management of Refractory Epilepsy





b. Surgery, Gama knife and neural stimulation (Vagus, 
DBS) 
c. Seizure prediction and prevention 
d. Gene therapy 
e. Stem cell therapy 
f. Pharmacogenetics
a) Second Line Drugs
The chances of the addition of a second-line drug 
resulting in a 50% reduction of seizures is 20-50%, 
however, the chances of the patient becoming seizure 
free is less than 10% (27), (33).
1) IVIG Treatment
Immunological mechanisms have been suspected in 
the pathogenesis of epileptic seizures in some patients 
and in experimental animal models of epilepsy. The 
effects of globulin treatment in epilepsy were first 
studied by Pechadre et al. in 1977 (34). They observed 
the disappearance of seizures and EEG improvement 
in epileptic children treated with intramuscular 
immunoglobulin for allergic seasonal diseases. Since 
the initial report, IVIG has been employed in intractable 
epilepsy, West and Lennox-Gastaut Syndromes (LGS) 
(35).
There is no dose protocol for IVIG treatment. In the 
literature, every study has a different dose schedules 
and the total dose of IVIG varies between 0.3 and 6.8 g/
kg for a period of 0.15 to 12 months. The mean seizure 




The Ketogenic Diet (KD) has been used worldwide for 
the treatment of intractable childhood epilepsy (37), 
(38). However, the KD is not yet a convenient therapy, 
especially in older children and adolescents (39), (40). 
The Atkins diet induces a state of ketosis by providing 
a high fat content and few carbohydrates and it is 
suggested that this diet may control seizures through a 
mechanism similar to the KD (41).
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3) Prednisolone Treatment:
Steroids, including prednisolone and 
adrenocorticotrophic hormone (ACTH), have been 
usedin the treatment of epilepsy for over 68 years (42), 
(43) and are recognized as relatively safe and effective 
for infantile spasms (44). However, studies of the use 
of steroids in the treatment of epileptic conditions other 
than infantile spasms are limited (45).
Some studies have showed that after prednisolone 
treatment in cryptogenic epileptic encephalopathies 
other than infantile spasms, about 25% to 59% of  the 
children become seizure free and 11% to 40% show 
reductions in seizure frequency (45), (46), (47).
4) Herbal and Supplemental Treatments:
There are two documented herbal treatments for 
intractable epilepsies in Iran as follows: 
1) A double-blind study found that using the extract 
of the black seeds of the Nigella Sativa plant helped 
control seizures in children (48).
2) In a double-blind clinical trial, conducted as a pilot 
study, researchers concluded that the essential oil of 
Rosa Damascena had beneficial antiepileptic effect in 
children with refractory seizures (49).
In a study, administration of high dose oral pyridoxine 
as a therapeutic adjunct to routine AEDs for the 
treatment of recurrent intractable seizures was useful 
(50). Serum Selenium concentration was lower in 
patients with intractable epilepsies compared with the 
control group, in a case-control study (51). Results are 
inconsistent regarding whether the use of fish oil can 
decrease seizure frequency in people with epilepsy 
(52). Several studies by a single research group hint 
that supplement Melatonin may improve the quality of 
life in children with epilepsy (53). People with epilepsy 
should seek medical supervision before using any herbs 
or supplements.
b) Surgery 
Once the newer antiepileptic drugs have failed, 
the choice of treatment is surgical ablation of the 
epileptogenic area. The goal of epilepsy surgery is 
to identify the abnormal area of cortex from which 
the seizures originate and remove it without causing 
any significant functional impairments (54). Prior to 
surgery, the presurgical evaluation, which involves 
the collaboration of neurologists, electrophysiologists, 
neuropsychiatrists, neurosurgeons, and nurses, is used 
to determine if a patient has seizures that are appropriate 
for surgical management and, if so, the type of surgery 
most likely to succeed (55,56).
The primary components of the presurgical evaluation 
include a detailed clinical history and physical 
examination, advanced neuro-imaging, Video-EEG 
monitoring, neuropsychological testing and assessment 
of psychosocial functioning.
Major questions to be answered with this evaluation 
are:
1) Are the seizures focal or generalized?
2) If focal, are they temporal or extratemporal in 
origin?
3) Is there a lesion associated with the seizures?  
4) If surgery is undertaken what functional deficits, if 
any should be anticipated?
Types of surgical approaches are discussed in another 
review (54). 
c) Seizure Prediction and Prevention
What if there is no surgically remediable lesion 
and the patient continues to have frequent seizures?
Seizures occurring without warning are the most 
disabling aspect. On demand release of short acting drug 
or electrical stimulation during the preictal state would 
prevent seizure (57). Trials are being conducted for 
early seizure detection through implanted intracranial 
electrodes and prevention of the seizure by responsive 
electrical stimulation (58), (59). Initial reports have 
shown reduction of seizures by 50% or more in over 
40% of refractory epilepsy patients (60).
d) Gene Therapy
The goal of gene therapy in epilepsy is for sustained 
anticonvulsant, and antiepileptogenic effect, 
and to block the progression of the disease. The 
GABAergic system is the first target for gene therapy 
to increase GABA levels in the epileptogenic area. 
Implantation of genetically engineered inhibitory 
cells into the focus may become an option (61).
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e) Stem Cell Therapy 
Some authors review cell transplantation as an alternative 
approach to the treatment of epilepsy. Recent work in 
animal models shows  that grafted neuronal precursors 
that differentiate into inhibitory interneuron can increase 
the level of local inhibition. Grafts of these inhibitory 
neurons could help restore equilibrium in temporal lobe 
epilepsy (62). Neuronal precursor cells derived from 
embryonic stem cells functionally integrate into the host 
brain tissue after transplantation (63). 
f) Pharmacogenetics
Some patients simply do not respond to AEDs right 
from the start and there are some other patients who are 
severely allergic to some AEDs, while the majority can 
tolerate them. This difference in response or sensitivity 
is partially due to genetic variations. The ultimate goal 
of pharmacogenetics is to use the genetic make up of 
individuals, to predict drug response and efficacy, and to 
predict potential adverse drug reactions (64). So far, the 
emphasis is on the control of seizures, i.e. antiepileptic, 
which is now shifted to prevention of epilepsy, i.e. 
antiepileptogenic which also means a cure, not just 
symptom control (65). 
In conclusion, we believe that diagnosis of intractable 
epilepsy should be firmly ascertained in the first place. 
Conditions which mimic epilepsy such as: breath 
holding spells, faint, sleep disorders, movement 
disorder, etc,… should be ruled out. Those cases whose 
seizures recurrence are due to inadequate drug dosage 
or secondary to using inappropriate drug for the seizure 
type which affects the patient, should be recognized.
Upon reaching the diagnosis of refractory epilepsy, the 
best way of management of any individual child should 
be delineated.
References
1. Berg AT,Kelly MM. Defining intractability: comparisons 
among published definitions. Epilepsia 2006; 47: 431–
436. 
2. Aicardi J. Epilepsy in children. 12th ed. Lippincott-
Raven:Philadelphia;2004.P.351–352.
3. Ko  TS, Holmes GL. EEG and clinical predictors 
of medically intractable childhood epilepsy. Clin 
Neurophysiol 1999;110:1245–1251.
4. Brodie MJ, Leach JP. Success or failure with antiepileptic 
drug therapy. Neurology 2003; 60: 162–164.
5. Kwan P, Brodie MJ. Early identification of refractory 
epilepsy. N Engl J Med 2000; 342: 314–319. 
6. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: 
response to sequential treatment schedules. Eur J Neurol 
2006;13:277–282.
7. Fanga PC, Chenb YJ, Leec IC. Seizure  precipitants in 
children  with intractable epilepsy. Brain and Development 
2008 Sept;30(8):527-532.
8. Mattson RH, Cramer JA, Collins JF. Prognosis for total 
control of complex partial and secondarily generalized 
tonic clonic seizures. Neurology 1996;47:68–76.
9. Alving J. What is intractable epilepsy? In: Johannessen 
SI (eds). Intractable epilepsy. Wrightson Biomedical 
Publishing:Petersfield;1995.P.1–12.
10. Gururaja A, Sztrihab L, Hertecantb J, Eapenc V. Clinical 
predictors of intractable childhood epilepsy. Journal of 
Psychosomatic Research 2006 September ;61(3):343-
347. 
11. Wirrell E, Farrell K, Whiting S. The epileptic 
encephalopathies of infancy and childhood. Can J Neurol 
Sci 2005;32:409–418.
12. Berg AT, Levy SR, Novotny EJ, Shinnar S. Predictors 
of intractable epilepsy: a case control study. Epilepsia 
1996;37:24–30.
13. Holmes GL. Epilepsy in the developing brain: lessons 
from the laboratory and clinic. Epilepsia 1997;38:12–
30.
14. Jeavons PM. Non-epileptic attacks in childhood. In: 
Rose FC, ed. Research progress in epilepsy. Pitman: 
London;1983.P.224-30.
15. Robinson R. When to start and stop anticonvulsants. In: 
Meadow R, ed. Recent advances in paediatrics. Vol 7. 
Churchill Livingstone: Edinburgh; 1984.P.155-74.
16. Krumholz A. Nonepileptic seizures: diagnosis and 
management. Neurology 1999; 53(suppl 2):76–83.
17. Lesser RP. Psychogenic seizures. Neurology 1996; 46: 
1499–507.
18. Sankar R, Koh S, Wu J, Menkes JH. Paroxymal disorder. 
Child Neurology;2006.P.857-942.
19. Sisodiya SM, Lin WR, Hurcing Rd. Drug resistance in 
epilepsy: expression of drus resistance protein in common 
INTRACTABLE EPILEPSY IN CHILDREN
13Iran J Child Neurology   Vol4 No3 Nov  2010
INTRACTABLE EPILEPSY IN CHILDREN
causes of refractory epilepsy. Brain 2002:125:22-31. 
20. Pedly TA, Hirano M. Is refractory epilepsy due to 
genetically determined resistance to antiepileptic drugs? 
N Eng J Med 2003:348;1680-1482.
21. Goutieres F, Aicardi J. Atypical presentations of 
pyridoxine dependent seizures: a treatable cause of 
intractable epilepsy in infants. Ann Neurol 1985;17:117-
20.
22. Philippa B. Mills1, Emma J. Footitt1, Kevin A. Mills1, 
Karin Tuschl1, Sarah Aylett1, et al. Genotypic and 
phenotypic spectrum of pyridoxine-dependent epilepsy 
(ALDH7A1 deficiency). Brain: A Journal of Neurology 
2010 June;133(7):2148-2159.
23. Akhondian j. A case report of pyridoxine dependent 
seizure. Journal of Kerman University of Medical 
Sciences 2001 Spring;8(2):118-122.
24. Kliegman R, Behrman R, Janson H, Stanton B. 
Nelson textbook of pediatrics. 18th ed. Saunders: 
Philadelphia;2007.P.2457-8.
25. Kochen S, Giagante B, Oddo S. Spike-and-wave 
complexes and seizure exacerbation caused by 
carbamazepine. Eur J Neurol 2002;9:41-47.
26. Vendrame M, Khurana DS, Cruz M, Melvin J, Valencia 
I, Legido A. Aggravation of seizures and/or EEG features 
in children treated with oxcarbazepine monotherapy. 
Epilepsia 2007;48:2116-2120.
27. Vijay Gupta, S.K Gupta DM, Rajinder Gupta, Intractable 
Epilepsy. JK-Practitioner 2005;12(2):105-107.
28. Schmidt D. Reduction of two-drug therapy in intractable 
epilepsy. Epilepsia 1983;24:368-76.
29. J H Livingston. Management of intractable epilepsy. 
Arch Dis Child 1991;66:1454-1456. 
30. Akhondian J, Heidarian F, Jafari SA. Predictive factors 
of pediatric intractable seizures. Arch Iran Med 2006 
Jul;9(3):236-9.
31. Sander JW. The natural history of epilepsy in the era of 
new antiepileptic drugs and surgical treatment. Epilepsia 
2003;44:17-20.    
32. Perucca E. Antiepileptic drug monotherapy versus 
polytherapy the on-going controversy. Epilepsia 1997;38:
S6-S8.          
33. Wieser HG. Epilepsy surgery: past, present and future. 
Seizure 1998;7:173-84.         
34. Pechadre JC, Sauvezie B, Osier C, Gibert J. Traitement 
des encephalopathies epileptiques de l’enfant par 
les gammaglobulines. Rev EEG Neurophysiol Clin 
1977;7:443-447.
35. Uran N, Serdarolu G, Serdarolu E, kalkan S, Özcan 
T. High-Dose intravenous immunoglobulin treatment 
in intractable childhood epilepsy. Turk J Med Sci 
2000;30:495-498.
36. Billiau AD, Witters P, Ceulemans B, Kasran A, Wouters 
C, Lagae L. Intravenous immunoglobulins in refractory 
childhood-onset epilepsy: effects on seizure frequency, 
EEG activity, and cerebrospinal fluid cytokine profile. 
Epilepsia 2007;48(9):1739-49.
37. Karimzadeh P, Tabarestani S, Mahvelati F, Tonekaboni 
SH, Ghofrani M. Intractable seizure disorders: Efficacy 
of the classic ketogenic diet. Iranian Journal of Child 
Neurology 2009;3(1):15-20.
38. Kossoff EH, McGrogan JR.Worldwide use of the 
ketogenic diet. Epilepsia 2005;46:280–289.
39. Freeman JM, Vining EPG, Pillas DJ, Pyzik PL, Casy 
JC, Kelly MT. The efficacy of the ketogenic diet-1998: 
a prospective evaluation of intervention in 150 children. 
Pediatrics 1998;102:1358–1363.
40. Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-
onset complications of the ketogenic diet for intractable 
epilepsy. Epilepsia 2004;45:1116–1124.
41. Stafstrom CE. Dietary approaches to epilepsy treatment: 
old and new options on the menu. Epilepsy Currents 
2004;4:215–222.
42. I. McQuarrie, J.A. Anderson and M.R. Ziegler, 
Observation on the antagonistic effects of posterior 
pituitary and cortico-adrenal hormones in the epileptic 
subject. J Clin Endocrinol 1942;2:406–410. 
43. Klein R, Livingston S. The effect of adrenocorticotrophic 
hormones in epilepsy. J Paediatr 1950;37:733–742. 
44. Baram TZ, Mitchell WG, Tourney A, Snead OC, Hanson 
RA, Horton EJ. High dose corticotrophin (ACTH) 
versus prednisone for infantile spasms. A prospective, 
randomized blinded study. Pediatrics 1996;97:375–379.
45. Youa SJ,  Jungb DE, Kimc HD, Leec HS, Kang HC. 
Efficacy and prognosis of a short course of prednisolone 
therapy for pediatric epilepsy. European Journal of 
Paediatric Neurology 2008 July;12(4):314-320.
14 Iran J Child Neurology   Vol4 No3 Nov  2010
46. Sinclair DB. Prednisone therapy in pediatric epilepsy. 
Pediatr Neurol 2003;28:194–198.
47. Verhelst H, Boon P, Buyse G. Steroids in intractable 
childhood epilepsy: clinical experience and review of the 
literature. Seizure 2005;14:412–421.
48. Akhondian J, Parsa A, Rakhshande H. The effect of 
Nigella sativa L. (black cumin seed) on intractable 
pediatric seizures. Med Sci Monit 2007;13:555-559.
49. Ashrafzadeh F, Rakhshandeh H, Mahmoudi E. Rosa 
Damascena oil: An adjunctive therapy for pediatric 
refractory seizures. Iranian Journal of Child Neurology 
2007 August;1(4):13-17.
50. Akhondian J. Talebi S. High dose oral pyridoxine for 
treatment of pediatric recurrent intractable seizures. 
Medical j of the Islamic Republic of Iran 2004;17:301-
305.
51. Ashrafi MR, Shabanian R, Abbaskhanian A, Nasirian 
A, Ghofrani M, Mohammadi M, et al. Selenium and 
intractable epilepsy: is there any correlation? Pediatr 
Neurol 2007 Jan;36(1):25-9.
52. Bromfield E, Dworetzky B, Hurwitz S. A randomized 
trial of polyunsaturated fatty acids for refractory epilepsy. 
Epilepsy Behav 2008;12:187-190.
53. Gupta M, Aneja S, Kohli K. Add-on melatonin improves 
sleep behavior in children with epilepsy: randomized, 
double-blind, placebo-controlled trial. J Child Neurol 
2005;20:112-115. 
54. Faraji M, Ashrafzadeh F, Faraji rad S. Epilepsy surgery in 
children. Iran J Child Neurology 2009 June;3(4):7-14.
55. Cendes F, Li LM, Watson C. Is ictal recording mandatory 
in temporal lobe epilepsy? Not when the interictal 
electroencephalogram and hippocampal atrophy coincide. 
Arch Neurol 2000;57:497-500. 
56. Cristina G, Carter O. Pharmacologically intractable 
epilepsy in children: Diagnosis and preoperative 
evaluation. Neurosurg Focus 2008;25(3):1-7.
57. Lehnertz K, Elger CE. Can epileptic seizures be predicted? 
Evidence from nonlinear time series analysis of brain 
electrical activity Phys Rev Lett 1998; 80: 5019-23.         
58. Fountas K, Smith JR. A novel closed-loop system in 
the control of focal, medically refractory epilepsy. Acta 
Neurochir Suppl 2007; 97: 357-62.         
59. Theodore WH, Fisher R. Brain stimulation for epilepsy. 
Acta Neurochir Suppl 2007;97:261-72.    
60. Worrell GA, Gardner AB, Stead SM, Hu S, Goerss S, 
Cascino GJ, et al. High-frequency oscillations in human 
temporal lobe: simultaneous microwire and clinical 
macroelectrode recordings. Brain 2008; 131: 928-37.
61. Hatase O, Itano T. Neural transplantation approaches for 
the treatment of epilepsy. Epilepsia 1995;36:269.   
62. Mark Richardson R, Nicholas M. Developing Cell 
Transplantation for Temporal Lobe  Epilepsy. Neurosurg 
Focus 2008;24(3):E17.
63. Shetty AK, Hattiangady B. Concise review: prospects of 
stem cell therapy for temporal lobe epilepsy. Stem Cells 
2007;25:2396-407.  
64. Delgado-Escueta AV, Bourgedis BFD Debate. Does 
genetic information in humans help us treat patients? 
Epilepsia 2008;49:13-24.         
65. Schwartzkroin PA. Arresting Epileptogenesis: The 
Current Challenge. Epilepsy Scientific Foundations of 
Clinical Practice. In: Rho JM, Sankar R, Cavazos JE, 
editors. Marcel Dekker;2006.         
INTRACTABLE EPILEPSY IN CHILDREN
